Merck (MRK) Gains A New Cancer Growth Story As Valuation Debate Heats Up

Merck’s Phase 3 melanoma vaccine success strengthens its oncology growth case, but Keytruda’s patent cliff, valuation, pricing and tariff risks challenge whether future pipeline gains justify the current share price.
Merck (MRK) is back in focus after reporting that its personalized mRNA cancer vaccine, intismeran autogene, combined with Keytruda, achieved statistically significant gains in keeping high-risk melanoma from recurring or spreading in a Phase 3 trial. The result follows powerful share-price momentum. Merck’s 30-day share-price return is 18.0%, its year-to-date return is 40.0%, and its one-year total shareholder return is 78.9%. Investors are weighing those gains, buyback activity and the possibility that future pipeline success is already reflected in the US$148.99 share price. Bulls argue that the vaccine result and Merck’s broad oncology portfolio justify a richer multiple. Bears point to Keytruda’s patent cliff and the stock’s proximity to all-time highs. The most followed Merck narrative estimates fair value at $136.85, below the last close, implying the shares are 9% overvalued. Through acquisitions and licensing, Merck has nearly tripled its late-phase pipeline since 2021. That pipeline is expected to represent a potential commercial opportunity exceeding $50 billion by the mid-2030s. Merck’s business-development strategy and robust research and development spending are intended to maintain and expand its leadership in oncology and other therapeutic areas, supporting long-term earnings growth and potentially improving net margins. However, the earnings step change embedded in the valuation is substantial. The investment case could change quickly if Keytruda’s loss of exclusivity is more damaging than expected, or if pricing and tariff pressures reduce projected margins. Investors should examine the two key rewards and five important warning signs behind the thesis. For broader healthcare exposure, Simply Wall St highlights 40 healthcare AI stocks. Its screener also includes 50 high-quality undervalued stocks, 12 dividend fortresses with resilient cash flows and elevated payout yields, and 78 resilient stocks with low-risk scores. This commentary is based on historical data and analyst forecasts, uses an unbiased methodology, and is not financial advice or a recommendation to buy or sell. It may not reflect the latest price-sensitive announcements or qualitative information. Simply Wall St has no position in stocks mentioned.
Continue your MRK research
Related News
Moderna's Melanoma Data Must Justify a Rally Analysts Do Not
Moderna rallied ahead of full Phase 3 melanoma data due Oct. 24, even as Goldman Sachs kept a Neutral rating and set a target well below the share price.
Biotech Catalysts Put Moderna and Achieve Life Sciences in Focus
A dense clinical calendar gives investors several binary events, led by Moderna and Merck’s melanoma program and Achieve Life Sciences’ response to an FDA manufacturing rejection.
Bank OZK's Rising Dividend Is Well Covered, but Credit Still Sets the Limit
Bank OZK raised its quarterly dividend for a 65th straight quarter. A payout near one-third of earnings provides room, while construction-loan credit remains the main constraint.
Novavax's Selloff Puts the Sanofi Partnership Under the Microscope
Novavax fell harder than the broader biotech market as investors reconsidered a partner-led business. Sanofi gives the company reach, but royalty and milestone timing remain outside Novavax's control.
Microsoft's Maia 300 Is an Efficiency Bet, Not an Nvidia Exit
Microsoft says Maia 300 will deliver 40% more tokens per megawatt than leading GPU systems and scale in 2027, but the company is still operating a mixed-chip cloud.
Adobe's AI Usage Is Growing Faster Than Its Backlog
Adobe delivered 13% reported revenue growth and more than 150% growth in AI-first ARR, but remaining performance obligations rose only 8%, keeping monetization under scrutiny.















Latest comments